REGENXBIO Inc. RGNX Balance Sheet

Regenxbio inc. (RGNX)

Balance Sheet / TTM

Mar'20	Dec'19	Sep'19	Jun'19	Mar'19	Dec'18	Sep'18	Jun'18	Mar'18	Dec'17	Sep'17	Jun'17	Mar'17	Dec'16	Sep'16	Jun'16	Mar'16	Dec'15	Sep'15	Dec'14
Assets
Current assets
Cash and cash equivalents
69,411	69,514	79,594	55,142	55,852	75,561	142,423	106,889	71,870	46,656	59,884	57,649	82,045	24,840	28,108	30,083	35,511	54,116	205,324	1,121
Marketable securities
209,846	226,696	252,125	286,354	229,373	244,200	230,166	179,605	157,997	114,122	106,778	104,434	63,764	64,714	63,662	64,124	65,544	60,025	8,025	-
Accounts receivable
44,522	38,148	19,175	9,679	8,372	8,587	2,626	739	25,976	473	884	50	228	1,032	679	783	2,036	2,136	-	-
Trade receivables
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	609	805
Related party receivables
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	750
Unbilled receivables
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	327
Prepaid expenses
7,422	6,475	6,920	6,036	6,292	5,734	6,308	3,690	4,667	5,334	3,225	2,432	1,843	1,775	2,171	1,480	1,189	1,020	1,400	28
Other current assets
7,032	4,199	2,414	2,281	3,995	3,831	4,834	2,347	2,208	1,412	1,390	1,252	922	1,010	2,000	1,437	1,300	851	127	-
Total current assets
338,233	345,032	360,228	359,492	303,884	337,913	386,357	293,270	262,718	167,997	172,161	165,817	148,802	93,371	96,620	97,907	105,580	118,148	215,485	3,031
Marketable securities
77,361	103,785	85,408	108,194	159,083	150,819	102,296	19,795	5,917	15,616	24,485	46,417	63,742	69,412	93,087	104,510	107,553	102,226	11,013	-
Accounts receivable
4,373	4,155	24,345	23,955	22,758	23,012	4,600	4,485	32,645	-	-	-	-	-	-	-	-	-	-	-
Property and equipment, net
30,414	28,973	28,287	27,330	23,140	28,702	19,856	16,698	14,829	13,977	11,548	11,524	11,061	9,324	5,804	2,864	1,328	538	385	0
Operating lease right-of-use assets
9,375	10,078	5,905	5,904	6,858	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Cost method investments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	300	300	300	303	303
Restricted cash
1,330	1,330	1,053	1,053	1,053	1,053	225	225	225	225	225	225	225	225	225	225	-	-	-	-
Deferred issuance costs
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	157
Other assets
2,850	4,555	4,011	3,211	2,255	2,315	1,650	1,514	883	862	836	393	297	400	239	266	223	168	128	-
Total assets
463,936	497,908	509,237	529,139	519,031	543,814	514,984	335,987	317,217	198,677	209,255	224,376	224,127	172,732	195,975	206,072	214,984	221,380	227,314	3,491
Liabilities and Stockholders’ Equity
Current liabilities
Accounts payable
9,008	6,409	9,608	5,851	4,204	4,412	5,214	4,230	5,007	4,832	2,594	3,948	4,129	1,543	5,376	2,076	1,113	1,014	3,105	334
Accrued expenses and other current liabilities
20,327	24,846	19,231	16,534	14,189	17,164	13,306	12,023	9,869	9,605	10,805	7,514	5,829	8,126	9,006	7,073	4,633	3,198	-	1,115
Deferred revenue
-	-	-	-	600	600	600	600	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease liabilities
2,454	2,421	2,506	2,276	2,397	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Accrued expenses
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,727	-
Due to related party under services agreement
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1,423
Related party promissory notes
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	2,403
Other related party payables
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	349	3,761
Advance payments
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	35	127	127	153
Total current liabilities
31,789	33,676	31,345	24,661	21,390	22,176	19,120	16,853	14,876	14,437	13,399	11,462	9,958	9,669	14,382	9,149	5,781	4,339	5,308	9,189
Deferred revenue
3,333	3,333	3,333	3,333	3,333	3,333	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Operating lease liabilities
7,990	8,874	4,320	4,654	5,483	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Deferred rent
-	-	-	-	-	1,098	1,116	1,192	1,225	1,211	1,205	1,217	1,271	1,326	1,367	748	602	233	198	-
Financing lease obligations
-	-	-	-	-	5,854	-	-	-	-	-	-	-	-	-	-	-	-	-	-
Other liabilities
672	1,828	1,800	1,900	1,772	2,500	691	720	1,776	-	-	-	-	-	-	-	-	-	-	-
Total liabilities
43,784	47,711	40,842	34,547	31,978	34,966	20,927	18,765	17,877	15,648	14,604	12,679	11,229	10,995	15,749	9,897	6,383	4,572	5,506	9,189
Commitments and contingencies (Note 7)
-	-	-	-	-	-	0	0	0	-	0	0	0	0	0	0	0	0	0	0
Convertible preferred stock, value
-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	12,593
Stockholders’ equity
Preferred stock; $0.0001 par value; 10,000 shares authorized, and no shares issued and outstanding at March 31, 2020 and December 31, 2019
-	-	-	-	-	-	0	0	0	-	0	0	0	0	0	0	0	0	0	0
Common stock; $0.0001 par value; 100,000 shares authorized at March 31, 2020 and December 31, 2019; 37,190 and 36,992 shares issued and outstanding at March 31, 2020 and December 31, 2019, respectively
4	4	4	4	4	4	4	3	3	3	3	3	3	3	3	3	3	3	3	-
Additional paid-in capital
638,588	627,810	619,386	610,891	602,425	592,580	582,249	386,110	378,954	371,497	366,960	363,393	350,047	276,354	274,349	272,476	270,711	269,144	268,275	10,518
Accumulated other comprehensive income (loss)
-580	205	363	471	-59	-720	-874	-771	-903	-715	-553	-646	-572	-33	853	521	275	-719	-26	-
Accumulated deficit
-217,900	-177,822	-151,400	-116,800	-115,317	-83,016	-87,322	-68,120	-78,714	-187,756	-171,759	-151,053	-136,580	-114,587	-94,979	-76,825	-62,388	-51,620	-46,444	-28,809
Total stockholders’ equity
420,152	450,197	468,395	494,592	487,053	508,848	494,057	317,222	299,340	183,029	194,651	211,697	212,898	161,737	180,226	196,175	208,601	216,808	221,808	-18,291
Total liabilities and stockholders’ equity
463,936	497,908	509,237	529,139	519,031	543,814	514,984	335,987	317,217	198,677	209,255	224,376	224,127	172,732	195,975	206,072	214,984	221,380	227,314	3,491